The Journal of Nuclear Medicine最新文献

{"title":"CD20-Targeted α-Radionuclides Synergize with Immune Checkpoint Inhibition to Treat Murine Lymphoma","authors":"Shyril O’Steen, Sang Y. Lee, Melissa L. Comstock, Allie R. Kehret, Yukang Lin, Donald K. Hamlin, Shannon L. Dexter, Daniel S. Hippe, Ted A. Gooley, D. Scott Wilbur, Yawen Li, Roland B. Walter, Brian Till, Johnnie J. Orozco, Damian J. Green","doi":"10.2967/jnumed.125.270515","DOIUrl":"https://doi.org/10.2967/jnumed.125.270515","url":null,"abstract":"<p>Treatment-refractory and relapsed disease remain leading causes of death for patients with lymphoma. Virtually all lymphomas are exquisitely sensitive to radiation, and α-particle radiation therapies are notably suited to targeting microcluster disease common in the setting of early relapse. Refractory or relapsed lymphoma may also involve the loss of therapeutic targets, but radiation may stimulate antitumor immune effects against disease with incomplete target expression. Such effects make immune checkpoint inhibition a compelling candidate for combination treatment. <strong>Methods:</strong> We evaluated the therapeutic efficacy of ²¹¹At-labeled antihuman CD20 monoclonal antibodies combined with immune checkpoint inhibition in human CD20 transgenic mice bearing murine lymphomas on opposing flanks that were either positive or negative for human CD20 expression (hCD20⁽⁺⁾ and hCD20^(–), respectively). <strong>Results:</strong> In the absence of ²¹¹At-hCD20, the antimurine checkpoint inhibitors PD1, CTLA4, CD47, and TIM3 had no efficacy given alone or in doublets. ²¹¹At-hCD20 given alone suppressed growth of both hCD20⁽⁺⁾ and hCD20^(–) tumors in a dose-dependent fashion, with predictably stronger suppression of hCD20⁽⁺⁾ tumors. Strikingly, the addition of PD1 alone or the PD1 plus CTLA4 doublet to low-dose ²¹¹At-hCD20 significantly strengthened suppression of both tumors and increased mouse survival. <strong>Conclusion:</strong> Future translation of this synergistic combination of α-radiotherapy and immune checkpoint inhibition holds promise for the treatment of high-risk aggressive lymphomas, including cases with postinduction minimal residual disease or antigen loss after targeted therapies.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146122132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network-Based Analysis for the Quantification of Brain and Body Immune Axes with Total-Body PET Imaging","authors":"Lucia Maccioni, Agne Knyzeliene, Carlos J. Alcaide-Corral, Victoria J.M. Reid, Timaeus E.F. Morgan, Martyn C. Henry, Andrew Sutherland, Mattia Veronese, Adriana A.S. Tavares","doi":"10.2967/jnumed.125.271514","DOIUrl":"https://doi.org/10.2967/jnumed.125.271514","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.271514absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146122342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of a Deep-Learning Coregistration Framework for Long–Axial-Field-of-View PET/CT Using Low-Radiation-Exposure Protocols Across Various Tracers","authors":"Zekai Li, Laura Providência, Philipp Mohr, Samaneh Mostafapour, Mostafa Roya, T. Samara Martinez-Lucio, Joost F. Somsen, Goudje L. van Leeuwen, Giordana Salvi De Souza, Joyce van Sluis, Andor W.J.M. Glaudemans, Rudi A.J.O. Dierckx, Jean-Paul P.M. de Vries, Gert Luurtsema, Riemer H.J.A. Slart, Adrienne H. Brouwers, Paul Schleyer, Maurizio Conti, Adriaan A. Lammertsma, Joshua Schaefferkoetter, Charalampos Tsoumpas","doi":"10.2967/jnumed.125.270420","DOIUrl":"https://doi.org/10.2967/jnumed.125.270420","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.270420absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146122133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SV2A PET Imaging Detects Severity-Dependent Synaptic Changes After Experimental Traumatic Spinal Cord Injury","authors":"Claudia Schrauwen, Nicolas Halloin, Annemie Van Eetveldt, Zoë Laermans, Winnok H. De Vos, Aleksandar Jankovski, Marleen Verhoye, Steven Staelens, Charles Nicaise, Daniele Bertoglio","doi":"10.2967/jnumed.125.271236","DOIUrl":"https://doi.org/10.2967/jnumed.125.271236","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.271236absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"91 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146122134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Ostrich to Mouse to Human: Translation of the Functional Liver PET Tracer [68Ga]Ga-TEoS-DAZA.","authors":"Julia Greiser,Robert Drescher,Mitali Sonawane,Christian Kuehnel,Steffen Wiegand,Olga Perkas,Marta Pomraenke,Thomas Winkens,Mari Teuter,Silav Al-Bazaz,Tobias L Ross,Jens P Bankstahl,Frank M Bengel,Adrian T Press,Michael Bauer,Martin Freesmeyer","doi":"10.2967/jnumed.125.271020","DOIUrl":"https://doi.org/10.2967/jnumed.125.271020","url":null,"abstract":"The aim of this study was to investigate the dynamic biodistribution of [68Ga]Ga-TEoS-DAZA, a functional liver PET tracer, in 2 preclinical models (ostrich embryos and mice) and in a healthy human liver donor to identify similarities and differences among the 3 species, which are relevant in translational nuclear medicine. Furthermore, the molecular pathway and metabolism of [68Ga]Ga-TEoS-DAZA was investigated. Methods: The dynamic biodistribution of [68Ga]Ga-TEoS-DAZA was determined via PET/CT in ostrich embryos, in healthy mice (C57BL/6), and in a healthy human liver donor. Hepatocyte transporter binding studies were performed in transfected HEK293t cells. Metabolite analysis was performed in samples from ostrich embryos and a healthy liver donor. Blocking studies against cyclosporine A were performed in ostrich embryos. Results: The biodistribution of [68Ga]Ga-TEoS-DAZA was comparable in ostrich embryos, healthy mice (C57BL/6), and the healthy donor. In all 3 species, the tracer showed specific uptake in liver tissue (30-40 %IA at time of peak) and subsequent biliary excretion, whereas less than 5 %IA activity was excreted renally. The hepatic transit time in mice was significantly faster than in ostrich embryos and human, with mice exhibiting a much shorter time-to-peak (1.7 min) than the other 2 species (15-21 min) and rapid clearance of the tracer from the liver into the intestines. [68Ga]Ga-TEoS-DAZA is a substrate for OATP1B3, with tracer uptake into the liver being hampered in the presence of cyclosporine A. Tissue samples revealed an as yet unknown radiometabolite of [68Ga]Ga-TEoS-DAZA, indicating hepatic metabolism. Conclusion: [68Ga]Ga-TEoS-DAZA was shown to be a suitable hepatobiliary tracer using both mice and ostrich embryos as preclinical models; however, there were limits in translatability in both models because of a distinctly faster hepatic uptake and biliary excretion (mice) or a slower biliary excretion (ostrich embryo) compared with that in the human.","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146072980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"68Ga-PSMA-11 PET/CT for Initial Staging of Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Predicts Overall Survival: An IAEA Multicenter Study.","authors":"Juliano J Cerci,Stefano Fanti,Enrique E Lobato,Rakesh Kumar,Jolanta Kunikowska,Akram Al-Ibraheem,Maisarah Nasir,Francisca Redondo Moneda,Osvaldo Garcia,Mohamad Haidar,Fuad Novruzov,Ozlem Kucuk,Umut Elboga,Murilo de Almeida Luz,Diana Paez","doi":"10.2967/jnumed.125.271173","DOIUrl":"https://doi.org/10.2967/jnumed.125.271173","url":null,"abstract":"Although multiple studies have demonstrated the accuracy of 68Ga-PSMA-11 PET/CT, its ability to predict survival outcomes and treatment response remains unclear. This study assessed the prognostic value of 68Ga-PSMA-11 PET/CT in staging unfavorable intermediate- or high-risk prostate cancer (PCa) in patients who are candidates for radical prostatectomy. Methods: This prospective multicenter trial supported by the International Atomic Energy Agency enrolled 775 patients across 11 countries with newly diagnosed, unfavorable intermediate- or high-risk PCa. Patients underwent 68Ga-PSMA-11 PET/CT, after which their disease was categorized as N0M0 (no involvement of local nodes and no metastases), N1M0 (pelvic lymph node involvement), or NxM1 (distant metastases). These findings were then compared with clinical follow-up data. Results: Biochemical recurrence rates were 35.4% (N0M0), 68.2% (N1M0), and 77.2% (NxM1). Two-year event-free survival rates were 56.6%, 43.9%, and 26.0% in patients with N0M0, N1M0, and NxM1 disease, respectively. Two-year overall survival rates were 99.3% in patients with N0M0 disease, 99.2% in those with N1M0 disease, and 86.8% in those with NxM1 disease (P < 0.001). 68Ga-PSMA-11 PET/CT status was the only significant prognostic factor for survival outcomes. Conclusion: 68Ga-PSMA-11 PET/CT is a robust and independent prognostic marker in patients with unfavorable intermediate- or high-risk PCa and may help tailor treatments and improve outcomes.","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146072932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mass Dose Effects in FAP-Directed Imaging: Influence of Administered Dose of [68Ga]Ga-LNTH-1363S on Image Quality.","authors":"Johanna S Enke,Jan Baessler,Gitasha Chand,Lisa Glantschnig,Bing Bai,Karl Sjoestrand,Martin Trepel,Kelly Orcutt,Niklas Dreher,Marianne Patt,Alexander Dierks,Constantin Lapa","doi":"10.2967/jnumed.125.271511","DOIUrl":"https://doi.org/10.2967/jnumed.125.271511","url":null,"abstract":"Recent advances in fibroblast activation protein imaging have led to the development of new fibroblast activation protein-targeting radiotracers. This study investigates the mass dose effects of [68Ga]Ga-LNTH-1363S on image quality. Methods: In this retrospective evaluation of 39 patients with various oncologic diseases (including breast cancer and sarcoma), different administered mass doses (30, 75, 90, and 100 μg) of [68Ga]Ga-LNTH-1363S were visually and quantitatively (blood pool SUVmean, lesion SUVmax, and tumor-to-blood pool ratios [TBRs]) assessed. Results: Lower peptide masses were associated with prominent blood pooling in [68Ga]Ga-LNTH-1363S PET imaging and reduced TBRs, whereas higher mass doses yielded superior image quality because of lower mean tracer accumulation in the blood pool and therefore higher TBRs. Conclusion: These observations provide evidence that biodistribution and imaging quality are dependent on the administered mass dose. Further studies are warranted to validate these findings.","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146073054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [225Ac]Ac-PSMA Radiopharmaceutical Therapy.","authors":"Liam Widjaja,Sophie C Siegmund,Franz J Gildehaus,Astrid Delker,Nina-Sophie Schmidt-Hegemann,Martin G Pomper,Steven P Rowe,Ralph A Bundschuh,Vera Wenter,Gabriel T Sheikh,Konrad Klimek,Jozefina Casuscelli,Christian Stief,Mathias J Zacherl,Rudolf A Werner","doi":"10.2967/jnumed.125.270677","DOIUrl":"https://doi.org/10.2967/jnumed.125.270677","url":null,"abstract":"225Ac-labeled prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) has emerged as a promising treatment option in advanced metastatic castration-resistant prostate cancer. We aimed to identify predictors for outcome including established clinical and PSMA-directed imaging parameters at baseline. Methods: Twenty-six patients with metastatic castration-resistant prostate cancer who were receiving [225Ac]Ac-PSMA-I&T RPT were included in this retrospective monocentric study. In each patient, all metastases on pretherapeutic [18F]F-PSMA-1007 PET/CT were segmented, enabling assessment of averaged SUVmax, SUVmean, as well as summed PSMA tumor volume (PSMA-TV) and PSMA-total lesion quotient (PSMA-TLQ; defined as PSMA-TV divided by SUVmean). PET parameters were then correlated with the relative prostate-specific antigen (PSA) change after 2 cycles of [225Ac]Ac-PSMA-I&T RPT. In addition, the predictive values for early progressive disease (PD; defined as a PSA increase of more than 25% or PD according to RECIP 1.0) after 2 cycles, progression-free survival (PFS), and overall survival (OS) were explored. Results: SUVmax (r = -0.42, P = 0.031) and SUVmean (r = -0.4, P = 0.046) correlated significantly with PSA change after 2 cycles, but PSMA-TV (P = 0.51) and PSMA-TLQ (P = 0.83) did not. Eleven patients (42%) demonstrated early PD. SUVmax (odds ratio, 0.769; P = 0.032) and SUVmean (odds ratio, 0.427; P = 0.041) were predictive for early PD. SUVmean emerged as the strongest predictor for prolonged PFS (hazard ratio [HR], 0.501; P = 0.006) with SUVmax also trending toward significance (HR, 0.914; P = 0.054). Patients with a high SUVmean achieved a longer median PFS of 134 d compared with 39 d in patients with low SUVmean (HR, 0.369; P = 0.041). PSMA-TLQ (HR, 1.007; P = 0.027) and PSMA-TV (HR, 1.001; P = 0.037) were predictive for OS. Patients with a low PSMA-TLQ (reflecting low PSMA-TV in combination with high SUVmean) achieved a longer median OS of 375 d compared with 148 d in patients with high PSMA-TLQ (HR, 2.84; P = 0.043). Conclusion: In patients scheduled for [225Ac]Ac-PSMA-I&T RPT, SUVmean on pretherapeutic [18F]F-PSMA-1007 PET/CT is predictive for early treatment response by identifying individuals prone to early PD and shorter PFS. In addition, PSMA-TLQ is associated with OS. As such, pretherapeutic PSMA PET-based quantification may optimize patient selection for targeted α-RPT.","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"143 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146072983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head-to-Head Comparison of mpMRI, PSMA, GRPR PET/CT, and PET/CT Plus MRI for Local Staging of Primary Prostate Cancer and Their Prognostic Value.","authors":"Yujia Li,Jinhui Yang,Bei Chen,Ling Xiao,Zihe Wang,Ming Zhou,Axel Rominger,Kuangyu Shi,Robert Seifert,Xiaomei Gao,Yi Cai,Yongxiang Tang,Shuo Hu","doi":"10.2967/jnumed.125.271410","DOIUrl":"https://doi.org/10.2967/jnumed.125.271410","url":null,"abstract":"Accurate local staging of primary prostate cancer (PCa) is crucial for guiding therapeutic strategies. Current imaging methods, including MRI and PET/CT, may have variable accuracy in detecting key disease features. This head-to-head study compared the diagnostic performance of prostate-specific membrane antigen (PSMA), gastrin-releasing peptide receptor (GRPR) PET/CT, multiparametric MRI (mpMRI), and combined PET/CT plus MRI for local staging of intermediate-risk and high-risk PCa, along with their prognostic significance. Methods: In this retrospective analysis, patients with intermediate-risk or high-risk PCa underwent mpMRI, [68Ga]Ga-PSMA-617 PET/CT, and [68Ga]Ga-RM26 (GRPR-targeted) PET/CT before radical prostatectomy. Imaging findings were compared with whole-mount histopathology for local T stage, bilateral intraprostatic disease, extraprostatic extension, and seminal vesicle invasion. The prognostic value for predicting biochemical recurrence-free survival was assessed. Results: Among 81 eligible men, PSMA PET/CT showed higher overall accuracy than GRPR PET/CT (56% vs. 36%, P = 0.011) and improved detection of bilateral intraprostatic disease compared with mpMRI (72% vs. 54%, P = 0.024). In the pure acinar adenocarcinoma subgroup, PSMA PET/CT outperformed both mpMRI and GRPR PET/CT for overall accuracy (58% vs. 39% and 34%, P = 0.029 and 0.005, respectively). The combined PSMA PET/CT plus mpMRI further enhanced staging accuracy compared with mpMRI alone (61% vs. 41%, P = 0.002). Additionally, a local stage T3a or greater based on PSMA PET/CT plus mpMRI was an independent predictor of biochemical recurrence-free survival (hazard ratio, 4.277; P < 0.001), surpassing conventional clinicopathologic factors. Conclusion: PSMA PET/CT, especially when combined with mpMRI, offers superior accuracy in local staging and provides incremental prognostic value beyond standard clinicopathological parameters. Incorporating PET/MRI-derived local staging into clinical decision-making may improve patient stratification, guide surgical or focal therapy strategies, and ultimately enhance patient outcomes.","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"569 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146073009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Aldosterone-Producing Adrenal Adenomas Using [68Ga]Ga-Pentixafor PET/CT in an Australian Cohort.","authors":"Elisabeth Ng,Ian Jong,Kenneth K Lau,Muhammad Akram,James Morgan,Piero Nelva,Ian Simpson,Mohammad B Haskali,Peter J Fuller,Jimmy Shen,Jun Yang","doi":"10.2967/jnumed.125.271006","DOIUrl":"https://doi.org/10.2967/jnumed.125.271006","url":null,"abstract":"Primary aldosteronism (PA) is the leading endocrine cause of hypertension. Subtyping is critical for identifying unilateral aldosterone-producing adenomas, which can be surgically resected. Adrenal vein sampling (AVS), the current standard for subtyping, is resource-intensive and invasive. We evaluated 68Ga-pentixafor PET/CT as a noninvasive nuclear imaging alternative to AVS, assessing its diagnostic accuracy and acceptability compared with AVS in a multiethnic population. Methods: This prospective pilot study recruited adults with PA and an adrenal adenoma visible on CT. Unilateral disease was defined by a lateralization index (LI) of greater than or equal to 4 on AVS, performed before and after adrenocorticotropic hormone stimulation, confirmed by biochemical response after adrenalectomy. The PET LI was calculated using the SUVmax at 10 and 40 min after tracer injection. Participants with incomplete AVS or discordance between LIs before and after adrenocorticotropic hormone stimulation were excluded from the comparison of AVS and PET unless they underwent adrenalectomy. Receiver-operating-characteristic curves were constructed to assess the performance of different PET LIs for predicting PA subtype compared with AVS or surgical outcome. Results: 68Ga-pentixafor PET/CT and AVS were performed in 34 patients (median age, 60 y). Five were excluded from the analysis, leaving 15 bilateral and 14 unilateral (9 left, 5 right) cases on the basis of AVS. The median PET LI at 10 min was 1.4 (interquartile range [IQR], 1.3-2.0) in the AVS-lateralized group and 1.1 (IQR, 1.1-1.3) in the nonlateralized group (P = 0.014); at 40 min, the median PET LI was 1.5 (IQR, 1.3-1.8) and 1.1 (IQR, 1.0-1.2), respectively (P = 0.014). A PET LI of 1.5 at 10 min achieved 100% specificity and 50% sensitivity. A PET LI of 1.4 at 40 min had higher sensitivity (64%) and lower specificity (87%). Survey responses indicated that PET/CT was faster, better tolerated, and the preferred test by 28 of 29 participants. Conclusion: 68Ga-pentixafor PET/CT is well-tolerated and promising as a noninvasive tool for PA subtyping, demonstrating high specificity and moderate sensitivity for identifying aldosterone-producing adenomas.","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146073010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}